Table 4.

Statistical evaluation of the benefit of diverse chemotherapy regimens used for adjuvant treatment in patients with T4 UICC II

Group comparisons
		FUFOL		FUFOL + Oxaliplatin		Others + Oxaliplatin		Other substances		Substance unknown		No chemotherapy
	Chemotheraphy	Chi-		Chi-		Chi-		Chi-		Chi-		Chi-
	group	square	Sig.	square	Sig.	square	Sig.	square	Sig.	square	Sig.	square	Sig.
Long Rank	FUFOL			,072	,788	.	.	,013	,909	,563	,453	4,179	,041
(Mantel-Cox)	FUFOL + Oxaliplatin	,072	,788			,074	,785	,192	,661	,015	,901	3,934	,047
	Others + Oxaliplatin	.	.	,074	,785			,118	,732	.	.	,628	,428
	Other substances	,013	,909	,192	,661	,118	,732			,223	,636	4,370	,037
	Substance unknown	,563	,453	,015	,901			,223	,636			,681	,409
	No chemotheraphy	4,179	,041	3,934	,047	,628	,428	4,370	,037	,681	,409